Titan Medical Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Cary G. Vance
- Full Time Employees
- 49
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 76 Berkeley Street Toronto ON Canada M5A 2W7
- IPO Date
- Apr 28, 2008
- CIK
- 0000840551
- Website
- titanmedicalinc.com
- Similar Companies
- Business
- Titan Medical Inc. (TMDI) develops and commercializes robotic-assisted surgical technologies for minimally invasive surgery; its core product is the Enos system, a single-port robotic platform featuring a surgeon-controlled patient cart with 3D high-definition vision, multi-articulating instruments mimicking natural movements, and an ergonomic surgeon workstation for gynecologic, urologic, and general procedures such as hysterectomies, nephrectomies, gallbladder removals, and hernia repairs. Founded in 2008 and headquartered in Toronto, Ontario, Canada, the company targets hospitals and ambulatory surgical centers seeking cost-effective alternatives to multi-port systems like Intuitive Surgical's da Vinci, with operations focused primarily in North America and plans for global expansion upon regulatory approvals including FDA De Novo authorization. In March 2024, Titan entered a definitive amalgamation agreement with Conavi Medical Inc. to merge in an all-stock transaction, creating a combined entity emphasizing commercialization of Conavi's Novasight Hybrid System for intravascular imaging in coronary procedures using simultaneous IVUS and OCT technologies; the merger, progressing through shareholder approvals, amended financings including a $7.7 million private placement of subscription receipts closed in October 2024, and reduced minimum cash conditions, represents a strategic pivot from Enos development—halted in February 2023 amid financial constraints and a review process engaging over 40 counterparties—toward hybrid imaging with IP licensing deals in robotic surgery announced in May, June, and August 2023, while retaining a portfolio of 235 patents.
3 Common Myths About Penny Stocks Debunked
Titan Medical Inc. (TMDI) Q3 2022 Earnings Call Transcript
Titan Medical to Issue Third Quarter 2022 Financial Results on November 10, 2022
Titan Medical to Present at the H.C. Wainwright Global Investment Conference
Titan Medical Inc. (TMDI) CEO Cary Vance on Q2 2022 Results - Earnings Call Transcript
Titan Medical to Issue Second Quarter 2022 Financial Results on August 11, 2022
Titan Medical Inc. (TMDI) CEO Paul Cataford on Q1 2022 Results - Earnings Call Transcript
Titan Medical to Issue First Quarter 2022 Financial Results on May 12, 2022
Titan Medical Inc. (TMDI) CEO Paul Cataford on Q4 2021 Results - Earnings Call Transcript
Titan Medical Reports Operating and Financial Results for the Fourth Quarter and Year End 2021
Analysts Estimate Titan Medical Inc. (TMDI) to Report a Decline in Earnings: What to Look Out for
Robotics Investments In December 2021
Titan Medical to Participate in H.C. Wainwright BioConnect 2022 Virtual Investor Conference
Titan Medical Completes Final Milestone Under Development Agreement with Medtronic
Titan Medical: Developing Single-Access Robotic Assisted Surgical Technologies
Titan Medical Inc.'s (TMDI) CEO David McNally on Q3 2021 Results - Earnings Call Transcript
Titan Medical to Report Third Quarter 2021 Financial Results on November 11, 2021
Titan Medical's (TMDI) CEO David McNally on Q2 2021 Results - Earnings Call Transcript
Titan Medical Reports Second Quarter 2021 Financial Results
Titan Medical Announces Appointment of Tammy Carrea as Vice President of Quality and Regulatory Affairs